다단계 필터링 능력을 갖는 형태소 분석기의 설계 및 구현

여상화(Sang Hwa Yuh),김용호(Yong Ho Kim),이학주(Hak Joo Lee),이정현(Jung Hyun Lee) 한국정보과학회 1991 한국정보과학회 학술발표논문집 Vol.18 No.2

본 논문에서는 사전의 표제어에 접속 정보를 부여하지 않고 일반적인 품사 정보만을 수록하여 가능한 모든 결합을 찾는 형태소 분석기를 제안한다. 한 어절에서 추출된 형태소들로 원래의 어절이 형성 가능한가만을 조사하여 가능한 모든 결합을 얻고, 잘못된 결합은 형태소 분석기가 갖는 Filtering 능력을 이용하여 제거한다. Filtering은 1차로 어절 구조 규칙을, 2차로는 실질 형태소와 형식 형태소의 결합시 형태적인 제약을 통해 이루어진다. Filtering에 필요한 정보는 사전과 독립적으로 구성하므로, 사전의 구성, 확장, 수정이 용이하다. 한글 코드는 2바이트 조합형 코드를 사용하여 음절 단위로 처리하며 이를 위해 전편집(Pre-editing)과 후편집(Post-editing) 과정을 둔다. 어절의 형태는 프로그램과 독립적으로 저장함으로써 올바른 어절의 판단을 단순한 탐색 문제로 취급하고, 어절의 형태를 다르게 정의하는 경우 프로그램의 변경을 최소화한다. 실험 결과 예외적인 몇몇 어절의 제외한 대부분의 어절에서 가능한 모든 결합 형태를 얻을 수 있었다.

Apo-1/Fas (CD95) Gene Polymorphism in Korean Hepatocellular Carcinoma Patients

Kim, Sung-Soo,Hong, Seung-Jae,Ahn, Yun-Gul,Kim, Bong-Seog,Yuh, Young-Jin,Han, Kye-Young,Lee, Hee-Jae,Chung, Joo-Ho,Yim, Sung-Vin,Cho, Jae-Young,Park, Yeon-Hee The Korean Society of Pharmacology 2003 The Korean Journal of Physiology & Pharmacology Vol.7 No.1

It is well known that different expression of Apo-1/Fas (CD95) plays important roles in various tumors and hepatocellular carcinoma (HCC) pathogenesis. Apo-1/Fas mediated apoptosis is one of the important pathways of apoptosis and is known to mediate apoptotic cell death by fas ligand (FasL). To examine the possible relationship between Apo-1/Fas gene polymorphism and HCC susceptibility, MvaI restriction fragment length polymorphism (RFLP) of Apo-1/Fas gene was examined in 94 Korean HCC patients and 240 control subjects. No statistically significant difference in the genotypic distribution and allelic frequencies was found between the control and the HCC. It is, therefore, concluded that Apo-1/Fas gene polymorphism is not associated with HCC susceptibility. Further studies are needed in order to clarify the relationships between genotypes of Apo-1/Fas gene and HCC pathogenesis.

Multi-core MgO NPs@C core–shell nanospheres for selective CO₂ capture under mild conditions

Kim, Tae Kyung,Lee, Kyung Joo,Yuh, Junhan,Kwak, Sang Kyu,Moon, Hoi Ri The Royal Society of Chemistry 2014 NEW JOURNAL OF CHEMISTRY Vol.38 No.4

<P>The core–shell structures have attracted attention in catalysis, because the outer shells isolate the catalytically active NP cores and prevent the possibility of sintering of core particles during catalytic reaction under physically and chemically harsh conditions. We aimed to adopt this core–shell system for CO<SUB>2</SUB> sorption materials. In this study, a composite material of multi-core 3 nm-sized magnesium oxide nanoparticles embedded in porous carbon nanospheres (MgO NPs@C) was synthesized by a gas phase reaction <I>via</I> a solvent-free process. It showed selective CO<SUB>2</SUB> adsorption capacity over N<SUB>2</SUB> under mild regeneration conditions.</P> <P>Graphic Abstract</P><P>A composite material of 3 nm magnesium oxide nanoparticles embedded in carbon nanospheres showed selective CO<SUB>2</SUB> adsorption capacity over N<SUB>2</SUB>. <IMG SRC='http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=c4nj00067f'> </P>

Postoperative simultaneous integrated boost-intensity modulated radiation therapy for patients with locoregionally advanced papillary thyroid carcinoma: preliminary results of a phase II trial and propensity score analysis.

Lee, Eun Kyung,Lee, You Jin,Jung, Yuh-S,Ryu, Junsun,Kim, Tae Hyun,Lee, Chang Yoon,Ryu, Chang Hwan,Kim, Tae Sung,Kim, Seok Ki,Chung, Ki-Wook,Kim, Sang Soo,Kim, Dae Yong,Kim, Joo Young,Cho, Kwan Ho Issued for the Endocrine Society by the Williams & 2015 The Journal of clinical endocrinology & metabolism Vol.100 No.3

<P>With recent technical advances in radiotherapy (RT) planning, simultaneous integrated boost intensity modulated radiotherapy (SIB-IMRT) has made possible the delivery of high radiation dose to the tumor, minimizing surrounding normal tissues.</P>

Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)

( Jung Sun Kim ),( Tae Min Kim ),( Myoung Joo Kang ),( Sung Ae Koh ),( Hyunkyung Park ),( Seung-hyun Nam ),( Jae Joon Han ),( Gyeong-won Lee ),( Young Jin Yuh ),( Hee Jeong Lee ),( Jung Hye Choi ) 대한내과학회 2023 The Korean Journal of Internal Medicine Vol.38 No.5

Background/Aims: Little attention is paid to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Korea due to the rarity of the disease. With its rising incidence, we aimed to evaluate recent changes in treatment patterns and survival outcomes of patients with CLL/SLL. Methods: A total of 141 patients diagnosed with CLL/SLL between January 2010 and March 2020 who received systemic therapy were analyzed in this multicenter retrospective study. Results: The median patient age was 66 years at diagnosis, and 68.1% were male. The median interval from diagnosis to initial treatment was 0.9 months (range: 0-77.6 months), and the most common treatment indication was progressive marrow failure (50.4%). Regarding first-line therapy, 46.8% received fludarabine, cyclophosphamide, plus rituximab (FCR), followed by chlorambucil (19.9%), and obinutuzumab plus chlorambucil (GC) (12.1%). The median progression-free survival (PFS) was 49.3 months (95% confidence interval [CI], 32.7-61.4), and median overall survival was not reached (95% CI, 98.4 mo-not reached). Multivariable analysis revealed younger age (≤ 65 yr) (hazard ratio [HR], 0.46; p < 0.001) and first-line therapy with FCR (HR, 0.64; p = 0.019) were independently associated with improved PFS. TP53 aberrations were observed in 7.0% (4/57) of evaluable patients. Following reimbursement, GC became the most common therapy among patients over 65 years and second in the overall population after 2017. Conclusions: Age and reimbursement mainly influenced treatment strategies. Greater effort to apply risk stratifications into practice and clinical trials for novel agents could help improve treatment outcomes in Korean patients.

Single-Stage Posterior Approach for the En Bloc Resection and Spinal Reconstruction of T4 Pancoast Tumors Invading the Spine

Wang Zhi,Truong Van Tri,Liberman Moishe,Al-Shakfa Fidaa,Yuh Sung-Joo,Soder Stephan Adamour,Wu James,Sunna Tarek,Renaud-Charest Émilie,Boubez Ghassan,Shedid Daniel 대한척추외과학회 2022 Asian Spine Journal Vol.16 No.5

Study Design: Retrospective cohort study.Purpose: This study aimed to evaluate the outcomes of patients who had T4 Pancoast tumors invading the spine and underwent en bloc resection and spinal stabilization through a single-stage posterior approach.Overview of Literature: Surgical resection for Pancoast tumors affecting the spine has been successfully performed in two stages involving spinal reconstruction and tumor resection. However, reports have rarely presented the results of en bloc resection combined with spinal stabilization for T4 Pancoast tumors invading the spine through a single-stage posterior approach.Methods: Patients who had T4N0M0 Pancoast tumors invading the spine and underwent a single-stage posterior approach were retrospectively recruited. The following data were obtained and examined: demographics, tumor histology, preoperative and postoperative therapy, complications, spinal reconstruction technique, tumor resection extent, survival time, and disease recurrence.Results: Eighteen patients were included. The mean population age was 61±17 years, and the most common pathological type was adenocarcinoma (61.1%). Complete resection (R0) was obtained in 15 patients (83.3%), positive surgical margins (R1) were found in three patients (16.7%), and the 90-day mortality rate was 0%. Postoperative major complications were detected in 12 patients (66.7%), who required reoperation. The mean survival time was 67±24 months, but the median survival time was not reached. Among the patients, 10 (55.6%) are still alive at the end of the study. The 2- and 5-year actual survival rates were 59% (95% confidence interval [CI], 35.7%–82.3%) and 52.5% (95% CI, 28.4%–76.6%), respectively.Conclusions: <i>En bloc</i> resection and spinal stabilization through a single-stage posterior approach might be effective for T4 Pancoast tumors invading the spine.

Enhanced Visualization of the Cervical Vertebra during Intraoperative Fluoroscopy Using a Shoulder Traction Device

Truong Van Tri,Al-Shakfa Fidaa,Boubez Ghassan,Shedid Daniel,Yuh Sung-Joo,Wang Zhi 대한척추외과학회 2020 Asian Spine Journal Vol.14 No.4

Study Design: A retrospective, matched cohort study of a prospective database.Purpose: To evaluate the efficacy and safety of the Cervision system (Spinologics, Montreal, Canada), a new shoulder traction device that improves the fluoroscopic visualization of the lower cervical spine using caudal traction of the shoulders out of the radiographic field.Overview of Literature: Operating at a wrong level is a common error that may be committed by nearly 50% of surgeons during their career. Intraoperative fluoroscopy of the cervical vertebrae is an extremely important step in cervical spine surgery. Optimal lateral cervical radiography of the C1–T1 vertebrae is not always possible due to overlap of the shoulders.Methods: In this study, a group of patients (n=33, device group) underwent surgery with the new device used to apply caudal traction to both shoulders, and another group of patients (n=33, matched control group) had surgery with the tape traction. Data about the lowest vertebra visible on lateral fluoroscopic view, installation time, skin irritation under the traction area, and postoperative brachial palsy were recorded, and these parameters were analyzed using the <i>t</i>-test.Results: The mean numbers of visible cervical vertebra were 6.3±0.41 in the device group and 5.6±0.32 in the matched control group (<i>p</i> <0.01, unpaired <i>t</i>-test). The mean installation times were 83.9±5.15 minutes in the device group and 73.7±6.32 minutes in the matched control group (<i>p</i> <0.02). Seven patients from the matched control group presented with skin irritation. However, none of the patients from the device group had the condition (p =0.005, Pearson chi-square test). Postoperative brachial palsy was not observed in both groups.Conclusions: The Cervision system is more effective and superior to tape traction in pulling the shoulders down to improve the visualization of the cervical vertebra on lateral fluoroscopic view during cervical spine surgery.

Assessing the Performance of Prognostic Scores in Patients with Spinal Metastases from Lung Cancer Undergoing Non-surgical Treatment

Truong Van Tri,Al-Shakfa Fidaa,Roberge David,Masucci Giuseppina Laura,Tran Thi Phuoc Yen,Dib Rama,Yuh Sung-Joo,Wang Zhi 대한척추외과학회 2023 Asian Spine Journal Vol.17 No.4

Study Design: Retrospective study.Purpose: The purpose of this study was to see how well the Tomita score, revised Tokuhashi score, modified Bauer score, Van der Linden score, classic Skeletal Oncology Research Group (SORG) algorithm, SORG nomogram, and New England Spinal Metastasis Score (NESMS) predicted 3-month, 6-month, and 1-year survival of non-surgical lung cancer spinal metastases.Overview of Literature: There has been no study assessing the performance of prognostic scores for non-surgical lung cancer spinal metastases.Methods: Data analysis was carried out to identify the variables that had a significant impact on survival. For all patients with spinal metastasis from lung cancer who received non-surgical treatment, the Tomita score, revised Tokuhashi score, modified Bauer score, Van der Linden score, classic SORG algorithm, SORG nomogram, and NESMS were calculated. The performance of the scoring systems was assessed by using receiver operating characteristic (ROC) curves at 3 months, 6 months, and 12 months. The predictive accuracy of the scoring systems was quantified using the area under the ROC curve (AUC).Results: A total of 127 patients are included in the present study. The median survival of the population study was 5.3 months (95% confidence interval [CI], 3.7–9.6 months). Low hemoglobin was associated with shorter survival (hazard ratio [HR], 1.49; 95% CI, 1.00–2.23; p =0.049), while targeted therapy after spinal metastasis was associated with longer survival (HR, 0.34; 95% CI, 0.21–0.51; p <0.001). In the multivariate analysis, targeted therapy was independently associated with longer survival (HR, 0.3; 95% CI, 0.17–0.5; p <0.001). The AUC of the time-dependent ROC curves for the above prognostic scores revealed all of them performed poorly (AUC <0.7).Conclusions: The seven scoring systems investigated are ineffective at predicting survival in patients with spinal metastasis from lung cancer who are treated non-surgically.

만성 골수성 백혈병 경과 중에 발생한 말초 T 세포림프종 1 예

임충현(Chung Hyun Lim),김지현(Ji Hyun Kim),김선임(Sun Im Kim),정은주(Eun Ju Chung),윤범(Beom Yun),김응주(Eung Joo Kim),조혜제(Hye Jae Cho),유영진(Young Jin Yuh),김성록(Sung Rok Kim) 대한내과학회 2001 대한내과학회지 Vol.61 No.4

Lymphoid malignancies have been reported in association with chronic myelogenous leukemia, but the development of chronic myelogenous leukemia and T-cell lymphoma in the same patients is rare. We experienced a case of peripheral T-cell lymphoma developed in the course of chronic myelogenous leukemia. In December 1993, a diagnosis of chronic myelogenous leukemia was made. The patient was treated with hydroxyurea and busulphan. In June 1999, the patient was admitted because of a swelling in right submandibular area and throat pain. He underwent right tonsilectomy. The histologic and immunologic examination of tonsil revealed a peripheral T-cell lymphoma. This case is additional one to a few previously reported cases of concurrence of chronic myelogenous leukemia and T-cell lymphoma. (Korean J Med 61:444-448, 2001)

진행성 비소세포폐암 환자에서 Vinorelbine과 Ifosfamide 복합화학요법의 효과 및 안정성

윤범,김선임,김응주,임충현,유영진,김성록 인제대학교 백병원 2001 仁濟醫學 Vol.22 No.2

Objective: The cisplatin-based combination chemotherapy can improve survival rates of unresectable non-small cell lung cancer. However, the toxicity of cisplatin is substantial. We assessed the efficacy and toxicity of vinorelbine and ifosfamide combination chemotherapy for the unresectable non-small cell lung cancer. Methods and Materials: Patients with unresectable biopsy-proven non-small cell lung cancer who had measurable lesion entered onto this study. From January 1998 to March 1999, 18 patients was enrolled onto this study, and the response was evaluable in 16 patients. The treatment consisted of vinorelbine 25 ㎎/㎡ on days 1 and 8 and ifosfamide 2 g/m2 with mesna 3 consecutive days from day 1. This schedule was repeated every 3 weeks. For patients with grade 4 myelosuppression, the dose of both vinorelbine and ifosfamide was reduced by 10% from the next cycle. Results: Partial response was observed in 7 patients (response rate: 41.1%, 95% C.I. 23.1∼66.8%) without complete response. The treatment-related mortality was observed in 1 patient, but the toxicities of this regimen were generally tolerable. Conclusion: Vinorelbine and ifosfamide combination chemotherapy was active and tolerable for inoperable non-small cell lung cancer.